Synthetic Biologics Inc (NYSEMKT:SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that Raymond D. Stapleton, PhD, has joined the Company as Senior Vice President, Manufacturing. Dr. Stapleton will lead the manufacturing team as the Company begins to prepare for late-stage clinical trials for its irritable bowel syndrome with constipation (IBS-C) and C. difficileprograms, and continues to move its monoclonal antibody (mAb) program forward to address Pertussis (whooping cough).
Dr. Stapleton is a pharmaceutical and biotechnology executive with over 15 years of experience at Merck & Co., Inc., in manufacturing, operations, quality, science, technology, engineering and process development. He most recently served as Executive Director, Global Vaccine Technology and Engineering. During his tenure at Merck, Dr. Stapleton contributed to the scale up, tech transfer and manufacturing product launch of multiple billion dollar franchises including ISENTRESS® (oral solid dosage for AIDs), GARDASIL® (HPV vaccine), KEYTRUDA® (anti-PD-1 cancer mAb therapy), and performed process development for the cholesterol lowering therapy MEVACOR® (lovastatin).
“Ray’s comprehensive manufacturing experience with both small and large molecules, as well as monoclonal antibodies, makes him the ideal candidate to join our team as we prepare to move our microbiome programs further along in the clinic,” said Jeffrey Riley, Chief Executive Officer at Synthetic Biologics. “His accomplishments in manufacturing and operations, as well as his education in the areas of microbiology and the microbiome, are expected to be beneficial additions to Synthetic Biologics’ continued successful product development. We believe Ray’s knowledge of manufacturing processes to support the commercialization of products, will be valuable as our team advances the SYN-010 therapeutic program to address IBS-C and the SYN-004 program to protect the microbiome and prevent C. difficile infection and antibiotic-associated diarrhea.”
Dr. Stapleton earned a PhD in microbial ecology from The Center for Environmental Biotechnology at The University of Tennessee, Knoxville, and a BS degree in biology from Mary Washington College. Subsequently, he was the recipient of an Alexander Hollaender Fellowship for post-doctoral studies in the Environmental Science Division at Oak Ridge National Laboratory. Dr. Stapleton has served for 10 years as a member of the Journal of Industrial Microbiology and Biotechnology review board and is an ad hoc reviewer for several journals including Environmental Science and Technology, Antonie von Leeuwenhook, and Enzyme and Microbial Technology. He has co-edited a book, and co-authored patents, as well as several peer-reviewed manuscripts and presentations. (Original Source)
Shares of Synthetic Biologics yesterday at $2.27. SYN has a 1-year high of $4.32 and a 1-year low of $1.34. The stock’s 50-day moving average is $2.53 and its 200-day moving average is $2.54.
On the ratings front, SYN has been the subject of a number of recent research reports. In a report issued on September 23, Griffin Securities analyst Keith Markey reiterated a Buy rating on SYN, with a price target of $9, which implies an upside of 296.5% from current levels. Separately, on September 21, BTIG’s Tim Chiang reiterated a Buy rating on the stock and has a price target of $5.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Keith Markey and Tim Chiang have a total average return of -28.5% and 15.3% respectively. Markey has a success rate of 15.8% and is ranked #3690 out of 3755 analysts, while Chiang has a success rate of 67.6% and is ranked #384.
Synthetic Biologics Inc is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases.